ConductScience.org, home

Paper31433752

Angiotensin Type 1 Receptor Blockers in Heart Failure.

Singh KD and 1 other. Curr Drug Targets, 2020. Cited by 27 papers, by iCite.

Cite this record

ConductScience Library. Angiotensin Type 1 Receptor Blockers in Heart Failure. Papers, record 31433752. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/31433752

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Angiotensin Type 1 Receptor Blockers in Heart Failure.
PubMed
Journal
Curr Drug Targets
PubMed
Year
2020
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
27
iCite
Relative citation ratio, by iCite
1.44
iCite
Revised in PubMed
2021-02-02
PubMed

Authors2

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Singh KDKhuraijam Dhanachandra
2Karnik SSSadashiva S

Source PubMed

Download CSV of authors

Topics7

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Angiotensin II Type 1 Receptor BlockersMajor topic
Heart FailureMajor topic
Angiotensin-Converting Enzyme Inhibitors
Humans
Receptor, Angiotensin, Type 1
Renin-Angiotensin System
Treatment Outcome

Source PubMed

Download CSV of topics

Grants4

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated bySource
R01 HL057470NHLBI NIH HHSUnited StatesR01HL057470PubMed and NIHNIH RePORTER
R01 HL115964NHLBI NIH HHSUnited StatesR01HL115964PubMed and NIHNIH RePORTER
R01 HL132351NHLBI NIH HHSUnited StatesR01HL132351PubMed and NIHNIH RePORTER
R01 HL142091NHLBI NIH HHSUnited StatesR01HL142091PubMed and NIHNIH RePORTER

Download CSV of grants

References78

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
120428262Role of the angiotensin II receptor blocker valsartan in heart failure.Exp Clin Cardiol2001https://conductscience.org/library/papers/20428262PubMed
214610160Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both.N Engl J Med2003https://conductscience.org/library/papers/14610160PubMed
321983097Effects of olmesartan and imidapril on the plasma adiponectin, P-selectin, and MDA-LDL levels of diabetic nephropathy patients.Clin Chim Acta2012https://conductscience.org/library/papers/21983097PubMed
417148616Angiotensinergic stimulation of vascular endothelium in mice causes hypotension, bradycardia, and attenuated angiotensin response.Proc Natl Acad Sci U S A2006https://conductscience.org/library/papers/17148616PubMed
59781693Angiotensinogen cleavage by renin: importance of a structurally constrained N-terminus.FEBS Lett1998https://conductscience.org/library/papers/9781693PubMed
611376628Eprosartan reduces cardiac hypertrophy, protects heart and kidney, and prevents early mortality in severely hypertensive stroke-prone rats.Cardiovasc Res2001https://conductscience.org/library/papers/11376628PubMed
721848583Systematic review of the effect of telmisartan on insulin sensitivity in hypertensive patients with insulin resistance or diabetes.J Clin Pharm Ther2012https://conductscience.org/library/papers/21848583PubMed
87828295Losartan in heart failure. Hemodynamic effects and tolerability. Losartan Hemodynamic Study Group.Circulation1995https://conductscience.org/library/papers/7828295PubMed
926657004Angiotensin II receptor blocker irbesartan attenuates cardiac dysfunction induced by myocardial infarction in the presence of renal failure.Hypertens Res2016https://conductscience.org/library/papers/26657004PubMed
1015492298Mortality and morbidity reduction with Candesartan in patients with chronic heart failure and left ventricular systolic dysfunction: results of the CHARM low-left ventricular ejection fraction trials.Circulation2004https://conductscience.org/library/papers/15492298PubMed
1122119063Four-year clinical outcomes of the OLIVUS-Ex (impact of Olmesartan on progression of coronary atherosclerosis: evaluation by intravascular ultrasound) extension trial.Atherosclerosis2012https://conductscience.org/library/papers/22119063PubMed
1215370071Endothelial function and oxidative stress.Endothelium2004https://conductscience.org/library/papers/15370071PubMed
1321983318Azilsartan: a newly approved angiotensin II receptor blocker.Cardiol Rev2011https://conductscience.org/library/papers/21983318PubMed
1425637937
Clinical impacts of additive use of olmesartan in hypertensive patients with chronic heart failure: the supplemental benefit of an angiotensin receptor blocker in hypertensive patients with stable heart failure using olmesartan (SUPPORT) trial.
Eur Heart J2015https://conductscience.org/library/papers/25637937PubMed
1530206479Heart Failure with Mid-range Ejection Fraction: Lessons from CHARM.Card Fail Rev2018https://conductscience.org/library/papers/30206479PubMed
1612788798Newly recognized components of the renin-angiotensin system: potential roles in cardiovascular and renal regulation.Endocr Rev2003https://conductscience.org/library/papers/12788798PubMed
1727536242Azilsartan as a Potent Antihypertensive Drug with Possible Pleiotropic Cardiometabolic Effects: A Review Study.Front Pharmacol2016https://conductscience.org/library/papers/27536242PubMed
183280490Angiotensin converting enzyme inhibitors. Properties and side effects.Hypertension1988https://conductscience.org/library/papers/3280490PubMed
1928194766Significance of angiotensin 1-7 coupling with MAS1 receptor and other GPCRs to the renin-angiotensin system: IUPHAR Review 22.Br J Pharmacol2017https://conductscience.org/library/papers/28194766PubMed
2024705437The new Japanese Society of Hypertension guidelines for the management of hypertension (JSH 2014): a giant undertaking.Hypertens Res2014https://conductscience.org/library/papers/24705437PubMed

See all 78 referencesDownload CSV of references

Cited by16

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 27 citations.

PMIDTitleJournalYearIn PapersSource
41572764Geniposide Attenuates Post-Myocardial Infarction Cardiac Remodeling via Parkin-Dependent Suppression of Hyperactivated Mitophagy.Curr Med Chem2026https://conductscience.org/library/papers/41572764PubMed
41465213
Angiotensin-Converting Enzyme Inhibitors to Prevent Liver Fibrosis in Metabolic Dysfunction-Associated Steatotic Liver Disease: Scientific Speculation or an Opportunity to Improve Real Clinical Practice?
Int J Mol Sci2025https://conductscience.org/library/papers/41465213PubMed
41131867A Computational Journey Toward an Optimal Design for Metamaterial Epicardial Passive Sleeves.Adv Healthc Mater2026https://conductscience.org/library/papers/41131867PubMed
41035141Letter to the Editor: Safety of combination therapy of azilsartan medoxomil and amlodipine: a population-based cohort study.Epidemiol Health2025https://conductscience.org/library/papers/41035141PubMed
39097838Mathematical modeling for prediction of physicochemical characteristics of cardiovascular drugs via modified reverse degree topological indices.Eur Phys J E Soft Matter2024https://conductscience.org/library/papers/39097838PubMed
38590561Transcriptome and proteome analyses reveal that upregulation of GSTM2 by allisartan improves cardiac remodeling and dysfunction in hypertensive rats.Exp Ther Med2024https://conductscience.org/library/papers/38590561PubMed
38566963Omecamtiv Mecarbil in the treatment of heart failure: the past, the present, and the future.Front Cardiovasc Med2024https://conductscience.org/library/papers/38566963PubMed
37504538The Impacts of Animal-Based Diets in Cardiovascular Disease Development: A Cellular and Physiological Overview.J Cardiovasc Dev Dis2023https://conductscience.org/library/papers/37504538PubMed
37057101The history and mystery of sacubitril/valsartan: From clinical trial to the real world.Front Cardiovasc Med2023https://conductscience.org/library/papers/37057101PubMed
36534965Pathophysiology and pharmacology of G protein-coupled receptors in the heart.Cardiovasc Res2023https://conductscience.org/library/papers/36534965PubMed
36085147Potential of angiotensin II receptor blocker telmisartan in reducing mortality among hospitalized patients with COVID-19 compared with recommended drugs.Cell Discov2022https://conductscience.org/library/papers/36085147PubMed
35318654Structural perspectives on the mechanism of signal activation, ligand selectivity and allosteric modulation in angiotensin receptors: IUPHAR Review 34.Br J Pharmacol2022https://conductscience.org/library/papers/35318654PubMed
35033178
Design and rationale for a comparison study of Olmesartan and Valsartan On myocardial metabolism In patients with Dilated cardiomyopathy (OVOID) trial: study protocol for a randomized controlled trial.
Trials2022https://conductscience.org/library/papers/35033178PubMed
34445477The Role of Mitochondria-Derived Peptides in Cardiovascular Diseases and Their Potential as Therapeutic Targets.Int J Mol Sci2021https://conductscience.org/library/papers/34445477PubMed
34200402Exploiting Knowledge on Structure-Activity Relationships for Designing Peptidomimetics of Endogenous Peptides.Biomedicines2021https://conductscience.org/library/papers/34200402PubMed
33013358Endogenous CCN5 Participates in Angiotensin II/TGF-β1 Networking of Cardiac Fibrosis in High Angiotensin II-Induced Hypertensive Heart Failure.Front Pharmacol2020https://conductscience.org/library/papers/33013358PubMed

Download CSV of cited by

Genes14

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/31433752

GET https://conductscience.org/api/papers/v1/31433752/references?page=2